

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 1 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

IMPORTANT REMINDER:

This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted standards of medical practice, peer-reviewed medical literature, government agency/program approval status, and other indicia of medical necessity.

The purpose of this Clinical Policy is to provide a guide to medical necessity. Benefit determinations should be based in all cases on the applicable contract provisions governing plan benefits (“Benefit Plan Contract”) and applicable state and federal requirements including Local Coverage Determinations (LCDs), as well as applicable plan-level administrative policies and procedures. To the extent there are any conflicts between this Clinical Policy and the Benefit Plan Contract provisions, the Benefit Plan Contract provisions will control.

Clinical policies are intended to be reflective of current scientific research and clinical thinking. This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

SUBJECT:

Medical necessity determination for Intravitreal Injection Therapy (CPT 67028), Photodynamic (Visudyne) Therapy (CPT 67221, 67225), Intravitreal Implants (CPT 67027, 67028), and ophthalmic pharmaceuticals.

DESCRIPTION:

The Food and Drug Administration approved Macugen (effective 12/17/2004) and Lucentis (effective 6/30/2006) as treatments of exudative, "wet" Age-Related Macular Degeneration (ARMD) regardless of subtypes and size. The chemotherapy drug Avastin (repackaged for ophthalmic use in single-dose vials) is widely used off-label for treatment of exudative “wet” ARMD and has become standard of care. The Food and Drug Administration (FDA) approved Eylea (effective 11/21/2011) as treatment for exudative (wet) age-related macular

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 2 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

degeneration. Diagnoses not listed in the Indications for Coverage will be considered for medical necessity on a case-by-case basis. Approximately 90% of ARMD is the “dry,” atrophic form. The “wet” form destroys vision more quickly. This treatment involves intravitreal injection of a pharmacologic agent. Macugen (pegaptanib sodium injection), Lucentis (ranibizumab), Avastin (bevacizumab) or Eylea (aflibercept) is injected to target the underlying biology of wet ARMD. Follow-up and potential re-treatment is recommended as follows:

- Macugen (pegaptanib): Return exam with re-treatment every 6 weeks as indicated.
- Lucentis (ranibizumab): Return exam approximately 4 weeks after treatment; subsequent follow-up depends on the clinical findings and judgment of the treating ophthalmologist.
- Avastin (bevacizumab): Return exam approximately 4 to 8 weeks after treatment; subsequent follow-up depends on the clinical findings and judgment of the treating ophthalmologist.
- Eylea (aflibercept): Return exam with re-treatment every 4 weeks as indicated for the first 12 weeks; then every 8 weeks thereafter.

The Food and Drug Administration (FDA) approved Triesence (effective 11/29/2007) as treatment for ocular inflammatory conditions. Diagnoses not listed in the Indications for Coverage will be considered for medical necessity on a case-by-case basis.

The Food and Drug Administration (FDA) approved the corticosteroid Ozurdex (dexamethasone intravitreal implant) effective 2009 as treatment for macular edema following retinal vein occlusion and effective 2010 as treatment for noninfectious inflammation of the uvea (uveitis). Ozurdex is also approved for the treatment of diabetic macular edema in patients who are pseudophakic or are phakic and scheduled for cataract surgery. The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide applied to the periocular skin, eyelid and ocular surface are recommended to be given prior to the injection. Ozurdex is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 3 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases. Ozurdex is contraindicated in patients with advanced glaucoma and in patients whose posterior lens capsule is not intact. Adverse reactions associated with ophthalmic steroids including Ozurdex include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera.

The FDA approved Iluvien (Fluocinolone acetonide intravitreal implant, 0.19 mg) for the treatment of diabetic macular edema (effective 9/26/2014). Diabetic macular edema can occur during any stage of diabetic retinopathy and develops when blood vessels leak causing fluid accumulation and swelling, or edema, in the macula. Each Iluvien implant is designed to release submicrogram levels of the corticosteroid, fluocinolone acetonide (FAc), for 36 months. Iluvien is injected into the back of the eye with an applicator that employs a 25-gauge needle, which allows for a self-sealing wound. Iluvien is approved to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Patients are advised to have follow-up eye examinations at appropriate intervals following treatment with Iluvien.

On April 11, 2005, the U.S. Food and Drug Administration (FDA) approved Retisert (fluocinolone acetonide implant) as an orphan drug for the single indication of chronic non-infectious uveitis affecting the posterior segment of the eye. Significant differences between Retisert and Iluvien include: different dosages of the drug being delivered to different areas of the eye. Retisert is a .59 mg sterile implant designed to release fluocinolone acetate to the posterior segment of the eye over approximately 30 months while Iluvien is a 0.19 mg sterile implant in a 36 month drug delivery system injected directly into the vitreous.

Visudyne therapy is a two-step procedure. Following intravenous administration, Visudyne is activated by a non-thermal laser light. The process is known as

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 4 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

photodynamic therapy. Visudyne selectively targets abnormal blood vessels under the retina, resulting in a reduction in their growth, without affecting normal/healthy retina tissue. This, in turn, stops the leakage associated with wet AMD. However, it is important for patients to be diagnosed and treated early if they are to gain maximal benefit from treatment with Visudyne. Diagnostic examination including fluorescein angiograms or OCT and potential re-treatment occur for a period of at least two years.

The FDA approved aflibercept (Eylea®), ranibizumab (Lucentis®), pegaptanib (Macugen®) and verteporfin (Visudyne®) for the diagnoses indicated below:

FDA approved indication (X = FDA Indication)

Indication	Eylea	Lucentis	Macugen	Visudyne
Neovascular (Wet) Age-Related Macular Degeneration (AMD)	X	X	X	
Macular Edema Following Retinal Vein Occlusion	X	X		
Diabetic Macular Edema (DME)	X	X		
Diabetic Retinopathy in patients with DME	X	X		
Predominantly classic subfoveal choroidal neovascularization due to AMD, pathological myopia or presumed ocular histoplasmosis				X
Myopic Choroidal Neovascularization		X		

In the Comparison of AMD Treatments Trials study, the difference in mean visual acuity improvement for patients treated with Avastin compared to Lucentis was -1.4 letters (95% [CI], - 3.7 to 0.8) at two years. The proportion of patients with arteriothrombotic events was similar in the Lucentis-treated patients (4.7%) compared to the Avastin-treated patients (5.0%; p=0.89). The proportion of patients with one or more systemic serious adverse events was higher with Avastin (39.9%) than Lucentis (31.7%; adjusted risk ratio, 1.30; 95% CI, 1.07-1.57; p=0.009). Serious systemic adverse events included all-cause

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 5 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

mortality, non-fatal stroke, non-fatal myocardial infarction, vascular death, venous thrombotic events and hypertension.

In the ANti-VEGF Antibody for the Treatment of Predominantly Classic CHORoidal Neovascularisation in AMD (ANCHOR) trial, the number of patients that lost fewer than 15 letters at 12 months was achieved by 96.4% of patients treated with Lucentis 0.5 mg compared to 64.3% of patients treated with Visudyne ($p < 0.001$). Rate of intraocular inflammation was higher for patients treated with Lucentis 0.5 mg at 15% compared to Visudyne at 2.8%.

In the VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet Age- Related Macular Degeneration (VIEW)-1 trial, the difference in the number of patients who lost fewer than 15 letters at 52 weeks between Eylea every 8 weeks compared to Lucentis was 0.6% (95.1% CI -0.32, 4.4). In terms of the number of patients who gained at least 15 letters, the mean difference between Eylea every 8 weeks was 6.6% (95.1% CI -1.0, 14.1). There were no adverse events that were found to be significant from the Lucentis arm.

In the VEGF Inhibition Study in Ocular Neovascularization (VISION) trial, the proportion of patients who lost fewer than 15 letters at week 54 for patients treated with Macugen 0.3 mg was 70%, compared to 55% for placebo ($p < 0.001$). There was a significant difference in adverse events between patients treated with Macugen compared to placebo for vitreous floaters (33% vs. 8%, $p < 0.001$), vitreous opacities (18% vs. 10%, $p < 0.001$), and anterior chamber inflammation (14% vs. 6%, $p = 0.001$).

In a trial comparing Eylea, Avastin and Lucentis, the Diabetic Retinopathy Clinical Research Network found in patients with diabetic macular edema that when the initial visual-acuity letter score was 78 to 69 (equivalent to approximately 20/32 to 20/40) (51% of participants), the mean improvement was 8.0 with Eylea, 7.5 with Avastin, and 8.3 with Lucentis ($P > 0.50$ for each pair wise comparison). When the initial letter score was less than 69 (approximately 20/50 or worse), the mean improvement was 18.9 with Eylea, 11.8 with Avastin, and 14.2 with Lucentis ($P < 0.001$ for Eylea vs. Avastin, $P = 0.003$ for Eylea vs. Lucentis, and $P = 0.21$ for Lucentis vs. Avastin).

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 6 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

POLICY/CRITERIA:

Envolve Vision Benefits, Inc. (Envolve Vision) will reimburse providers for medically indicated procedures. Envolve Vision reimburses providers for drugs when the conditions listed below are met. Providers should check with the full-service health plan for drug coverage and/or obtain written verification from patients stating acknowledgement of the non-covered benefit status of the drug.

- The Payor does not have a direct exclusion for ophthalmologic drugs and biologicals in the contract
- Ophthalmologic drugs and biologicals are not excluded from the capitation agreement
- They must meet the definition of drugs or biologicals
- They are of the type that are not usually self-administered
- Drugs that can be self-administered are not covered
- They meet all the general requirements for coverage of items as incident to a physician's services. Only injectable (including intravenous) drugs are eligible for inclusion under the "incident to" benefit.
- They are reasonable and necessary for the diagnosis or treatment of an ophthalmologic illness or injury for which they are administered according to accepted standards of medical practice
- They are not immunizations
- They have not been determined by the FDA to be less than effective
- No active hepatitis or clinically significant liver disease, unless cleared by an appropriate medical evaluation
- No porphyria or other porphyrin sensitivity

AUTHORIZATION PROTOCOLS:

Aflibercept (Eylea®), ranibizumab (Lucentis®), pegaptanib (Macugen®) and verteporfin (Visudyne®) require pre-authorization. The medical record must clearly document medical necessity of the procedure including any required diagnostic testing and frequency of treatments. The provider must submit Attachment A: Prior-Authorization for aflibercept (Eylea®), ranibizumab (Lucentis®), pegaptanib (Macugen®), verteporfin (Visudyne®) with medical

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 7 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

records for approval. Avastin (bevacizumab) does not require prior authorization. Services must be performed and documented in accordance with this policy.

Professional services provided by duly licensed eye care providers must be within the scope of licensure as defined by applicable State guidelines.

ATTACHMENTS:

Attachment A: Anti-VEGF PA Form

REFERENCES:

American Academy of Ophthalmology (AAO) Retina Panel, Preferred Practice Pattern® Guidelines, Age Related Macular Degeneration, San Francisco, CA: American Academy of Ophthalmology 2015, www.aao.org/ppp

NDC #00065-0543-01 Physician Office Fact Sheet, Triesence (triamcinolone acetate injectable suspension) 40 mg/mL

NDC #61755-005-02 Physician Office Fact Sheet, Eylea (aflibercept injection) 2mg/.05mL

NDC #0023-3348-07 Physician Office Fact Sheet, Ozurdex (dexamethasone intravitreal implant) .7mg/1

Department of Health and Human Services, Centers for Medicare and Medicaid Services, Medicare Learning Network, MLN Matters, MM8292. Release Date June 14, 2013, CR Transmittal # R2728CP and R155NCD

NDC #68611-0190-02 Fact Sheet Iluvien (fluocinolone acetonide intravitreal implant) 0.19mg

NDA 22315/S-009 Highlights of Prescribing Information for Ozurdex (dexamethasone intravitreal implant). 2014. Allergan, Inc.

Lucentis [Prescribing Information] South San Francisco, CA: Genentech, Inc.;

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 8 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

February 2015.

Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial. The IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC. *Ophthalmology*. 2012; 7:1399-1411. Epub 2012 May 11.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results. *Ophthalmology*; 2012; 7:1388-98.

Weigert G, Michels S, Sacu S, et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. *Br J Ophthalmol*. 2008 Mar; 92(3):356-360.

Bashshur Zf, Haddad Za, Schakal A, et al. Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: A One-year Prospective Study. *Am J Ophthalmol*. 2008;145:249-256.

Yazdani S, Hendi K, Pakravan M, et al. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. *J Glaucoma*. October-November 2009;18(8):632-637.

Brouzas D, Charakidas A, Moschos M, et al. Bevacizumab (Avastin®) for the management of anterior chamber neovascularization and neovascular glaucoma. *Clinical Ophthalmology*. 2009;3:685-688.

Moraczewski AL, Lee RK, Palmberg PF, et al. Outcomes of treatment of neovascular glaucoma with intravitreal vevacizumab. *Br J Ophthalmol*, 2009;93:589-593.

Costagliola C, Cipollone U, Rinaldi M, et al. Inravitreal bevacizumab

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 9 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

(Avastin®) injection for neovascular glaucoma: a survey of 23 cases throughout 12-month follow-up. Br J Clin Pharmacol, 2008;66(5):667-673.

di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248:785-791.

Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008 Jun;246(6):837-842.

Arevalo JF, Sanchez JG, Wu L, et al. Primary intravitreal bevacizumab for diffuse diabetic macular edema. Ophthalmology. August 2009;116(8):1488-1497.

Roh MI, Byeon SH, Kwon OW. Repeated intravitreal injection of bevacizumab for clinically significant diabetic macular edema. Retina, the Journal of Retinal and Vitreous Diseases. 2008; 28(9): 1314-1318.

Kook D, Wolf A, Kreutzer T, et al. Long-term effect of intravitreal bevacizumab (Avastin) in patients with chronic diffuse diabetic macular edema. Retina, the Journal of Retinal and Vitreous Diseases. 2008; 28(8): 1053-1060.
15. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;334:1432-1444.

Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 Dec 30;351(27):2805-16.

June Glassman AR et al. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. NEJM February, 2015 published online ahead of print (DOI: 10.1056/NEJMoa1414264)

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 10 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

Micromedex® Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed June 2016.

Clinical Pharmacology Web site. Available at: <http://cpip.gsm.com/>. Accessed June 14, 2016.

Envolve Pharmacy Solutions Clinical Policy aflibercept, ranibizumab, pegaptanib, verteporfin. Updated 5/2017.

CODING IMPLICATIONS:

Providers should report these procedures using CPT Codes 67027, 67028, 67221, or 67225 and the appropriate ICD-10 code.

INDICATIONS FOR COVERAGE:

Lucentis (Ranibizumab)

E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 11 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 12 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 13 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112	Central retinal vein occlusion, right eye, stable
H34.8120	Central retinal vein occlusion, left eye, with macular edema
H34.8121	Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8122	Central retinal vein occlusion, left eye, stable
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132	Central retinal vein occlusion, bilateral, stable
H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311	Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312	Tributary (branch) retinal vein occlusion, right eye, stable
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321	Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322	Tributary (branch) retinal vein occlusion, left eye, stable

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 14 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8331	Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332	Tributary (branch) retinal vein occlusion, bilateral, stable
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar
H35.351	Cystoid macular degeneration right eye
H35.352	Cystoid macular degeneration left eye
H35.353	Cystoid macular degeneration bilateral
H35.81	Retinal edema
H59.031	Cystoid macular edema following cataract surgery, right eye
H59.032	Cystoid macular edema following cataract surgery, left eye
H59.033	Cystoid macular edema following cataract surgery, bilateral

Macugen (Pegaptanib Sodium)

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 15 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 16 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 17 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 18 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar

Avastin (Bevacizumab)

E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 19 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral
E08.3591	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, right eye
E08.3592	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, left eye
E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, bilateral
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 20 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E09.3591	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E09.3592	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E10.3591	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E10.3592	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 21 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.3591	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye
E11.3592	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye
E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral
H21.1X1	Other vascular disorders of iris and ciliary body, right eye
H21.1X2	Other vascular disorders of iris and ciliary body, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 22 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H21.1X3	Other vascular disorders of iris and ciliary body, bilateral
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112	Central retinal vein occlusion, right eye, stable
H34.8120	Central retinal vein occlusion, left eye, with macular edema
H34.8121	Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8122	Central retinal vein occlusion, left eye, stable
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132	Central retinal vein occlusion, bilateral, stable
H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311	Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312	Tributary (branch) retinal vein occlusion, right eye, stable
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321	Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322	Tributary (branch) retinal vein occlusion, left eye, stable
H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8331	Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332	Tributary (branch) retinal vein occlusion, bilateral, stable
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 23 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar
H35.351	Cystoid macular degeneration right eye
H35.352	Cystoid macular degeneration left eye
H35.353	Cystoid macular degeneration bilateral
H35.81	Retinal edema
H59.031	Cystoid macular edema following cataract surgery, right eye
H59.032	Cystoid macular edema following cataract surgery left eye
H59.033	Cystoid macular edema following cataract surgery, bilateral

Trience (Triamcinolone Acetonide)

H20.011	Primary iridocyclitis, right eye
H20.012	Primary iridocyclitis, left eye
H20.013	Primary iridocyclitis, bilateral
H20.021	Recurrent acute iridocyclitis, right eye
H20.022	Recurrent acute iridocyclitis, left eye
H20.023	Recurrent acute iridocyclitis, bilateral
H20.031	Secondary infectious iridocyclitis, right eye
H20.032	Secondary infectious iridocyclitis, left eye
H20.033	Secondary infectious iridocyclitis, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 24 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H20.041	Secondary noninfectious iridocyclitis, right eye
H20.042	Secondary noninfectious iridocyclitis, left eye
H20.043	Secondary noninfectious iridocyclitis, bilateral
H20.051	Hypopyon, right eye
H20.052	Hypopyon, left eye
H20.053	Hypopyon, bilateral
H20.11	Chronic iridocyclitis, right eye
H20.12	Chronic iridocyclitis, left eye
H20.13	Chronic iridocyclitis, bilateral
H20.21	Lens-induced iridocyclitis, right eye
H20.22	Lens-induced iridocyclitis, left eye
H20.23	Lens-induced iridocyclitis, bilateral
H20.821	Vogt Koyanagi syndrome, right eye
H20.822	Vogt Koyanagi syndrome, left eye
H20.823	Vogt Koyanagi syndrome, bilateral.
H44.131	Sympathetic uveitis right eye
H44.132	Sympathetic uveitis left eye
H44.133	Sympathetic uveitis bilateral
M31.5	Giant cell arteritis with polymyalgia rheumatica

Iluvien (Fluocinolone Acetonide 0.19mg)

E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 25 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 26 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 27 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral

Retisert (Fluocinolone Acetonide 0.59mg)

H30.011	Focal chorioretinal inflammation, justapapillary right eye
H30.012	Focal chorioretinal inflammation, justapapillary left eye
H30.013	Focal chorioretinal inflammation, justapapillary bilateral
H30.021	Focal chorioretinal inflammation of posterior pole right eye
H30.022	Focal chorioretinal inflammation of posterior pole left eye
H30.023	Focal chorioretinal inflammation of posterior pole bilateral
H30.031	Focal chorioretinal inflammation peripheral right eye
H30.032	Focal chorioretinal inflammation peripheral left eye
H30.033	Focal chorioretinal inflammation peripheral bilateral
H30.041	Focal chorioretinal inflammation, macular or paramacular right eye
H30.042	Focal chorioretinal inflammation, macular or paramacular left eye
H30.043	Focal chorioretinal inflammation, macular or paramacular bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 28 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H30.111	Disseminated chorioretinal inflammation of posterior pole right eye
H30.112	Disseminated chorioretinal inflammation of posterior pole left eye
H30.113	Disseminated chorioretinal inflammation of posterior pole bilateral
H30.121	Disseminated chorioretinal inflammation peripheral right eye
H30.122	Disseminated chorioretinal inflammation peripheral left eye
H30.123	Disseminated chorioretinal inflammation peripheral bilateral
H30.131	Disseminated chorioretinal inflammation generalized right eye
H30.132	Disseminated chorioretinal inflammation generalized left eye
H30.133	Disseminated chorioretinal inflammation generalized bilateral
H30.101	Unspecified disseminated chorioretinal inflammation right eye
H30.102	Unspecified disseminated chorioretinal inflammation left eye
H30.103	Unspecified disseminated chorioretinal inflammation bilateral
H30.141	Acute posterior multifocal placoid pigment epitheliopathy right eye
H30.142	Acute posterior multifocal placoid pigment epitheliopathy left eye
H30.143	Acute posterior multifocal placoid pigment epitheliopathy bilateral

Eylea (Aflibercept)

E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 29 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye
E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 30 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 31 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112	Central retinal vein occlusion, right eye, stable
H34.8120	Central retinal vein occlusion, left eye, with macular edema
H34.8121	Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8122	Central retinal vein occlusion, left eye, stable
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132	Central retinal vein occlusion, bilateral, stable
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 32 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar
H35.351	Cystoid macular degeneration right eye
H35.352	Cystoid macular degeneration left eye
H35.353	Cystoid macular degeneration bilateral
H59.031	Cystoid macular edema following cataract surgery, right eye
H59.032	Cystoid macular edema following cataract surgery, left eye
H59.033	Cystoid macular edema following cataract surgery, bilateral

Visudyne (Verteporfin)

B39.5	Histoplasmosis duboisii
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 33 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar
H44.21	Degenerative myopia right eye
H44.22	Degenerative myopia left eye
H44.23	Degenerative myopia bilateral

Ozurdex (Dexamethasone): Codes E08.3211-E11.3513 must be billed in conjunction with pseudophakia (Z96.1) or the member must be scheduled for cataract surgery.

E08.3211	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, right eye
E08.3212	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, left eye
E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3311	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E08.3312	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3411	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, right eye
E08.3412	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, left eye
E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3511	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, right eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 34 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E08.3512	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, left eye
E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, bilateral
E09.3211	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3212	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3311	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E09.3312	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3411	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E09.3412	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E09.3511	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E09.3512	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E10.3211	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E10.3212	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 35 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E10.3311	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E10.3312	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3411	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E10.3412	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye
E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E10.3511	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E10.3512	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
E11.3211	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E11.3212	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, left eye
E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3311	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye
E11.3312	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye
E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3411	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye
E11.3412	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 36 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E11.3511	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye
E11.3512	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye
E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112	Central retinal vein occlusion, right eye, stable
H34.8120	Central retinal vein occlusion, left eye, with macular edema
H34.8121	Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8122	Central retinal vein occlusion, left eye, stable
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132	Central retinal vein occlusion, bilateral, stable
H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311	Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312	Tributary (branch) retinal vein occlusion, right eye, stable
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321	Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322	Tributary (branch) retinal vein occlusion, left eye, stable
H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H44.131	Sympathetic uveitis right eye

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 37 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018

H44.132	Sympathetic uveitis left eye
H44.133	Sympathetic uveitis bilateral
H44.111	Panuveitis right eye
H44.112	Panuveitis left eye
H44.113	Panuveitis bilateral
H34.8331	Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332	Tributary (branch) retinal vein occlusion, bilateral, stable
H35.81	Retinal edema

REVIEW/REVISION LOG

Revision:	Date
Revise criteria.	04/2018
Annual review; update references	01/2018
Update medical indications; Addition of Attachment A; Update Prior-Authorization requirements; Update references; Update medical indications for Ozurdex.	05/2017
Update medical indications and remove unspecified diagnoses; update references; remove Attachment A.	12/2016
Update medical indications	05/2016
Addition of covered codes for administration of Iluvien and Retisert, update diagnoses to ICD-10, update covered codes for Lucentis and Macugen and update references, rebrand to new corporate name	12/2015
Addition of Attachment A with ICD9/ICD10 code crosswalk	12/2014
Addition of covered codes for administration of Eylea.	07/2014
Addition of Ozurdex intravitreal implant with indications; update to references	12/2013
Addition of OCT as monitoring procedure for photodynamic therapy.	07/2013

**ENVOLVE VISION BENEFITS, INC.
INCLUDING ALL ASSOCIATED SUBSIDIARIES
CLINICAL POLICY AND PROCEDURE**

DEPARTMENT: Utilization Management	DOCUMENT NAME: Photodynamic and Intravitreal Therapies and Pharmaceuticals
PAGE: 38 of 38	REFERENCE NUMBER: OC.UM.CP.0040
EFFECTIVE DATE: 09/01/2017	REPLACES DOCUMENT: 210-UM-R3, 229-UM-R7, 3030-MM-R4, 3051-MM-R3, 3070-MM-R3, 3076-MM-R3, 3087-MM
RETIRED:	REVIEWED: 10/30/2017
SPECIALIST REVIEW: Yes	REVISED: 03/2018
PRODUCT TYPE: All	COMMITTEE APPROVAL: 04/09/2018